I am meeting with Dr. Ash Tewari of Weill Cornell/Columbia Presbyterian and
Dr. Bertrand Guillonneau at Memorial Sloan Kettering as potential surgeons.
I have heard very positive news about both of them.
I would appreciate any experience you may have had with either of them or
information you may want to share.
Thank you.
Michael K
Gleason: 3+3=6
Stage: T1c
PSA: 3.23
Cancer in right apex, high-grade PIN in 2 cores
Age: 60 in otherwise excellent health, family of centenarians
One core 5% to 10% of "moderately differentiated invasive adenocarcinoma of
intermediate nuclear grade having architectural features of Gleason's
pattern 3. No perineural invasion is identified."
David S. - 07 Jul 2005 12:16 GMT
Do not know those physicians, so I cannot help you there. But good luck.
Your numbers are about the same as mine two years ago, then age 55. I am
sure you will do fine and rival the longevity of your relations.
> I am meeting with Dr. Ash Tewari of Weill Cornell/Columbia Presbyterian and
> Dr. Bertrand Guillonneau at Memorial Sloan Kettering as potential surgeons.
[quoted text clipped - 14 lines]
> intermediate nuclear grade having architectural features of Gleason's
> pattern 3. No perineural invasion is identified."
ron - 07 Jul 2005 16:55 GMT
Hi Michael...I presume you are meeting with them to discuss LRP. Since
your biopsy identified cancer in the prostatic apex you might want to
ask them about positive apical margins with LRP vs. open RP...Best
wishes and good health, Ron
>From yesterdays Medscape: Medscape Review of 2005 AUA Meeting
http://www.medscape.com/viewarticle/507264?src=mp
snip
The positive surgical margin rate continues to be higher with
laparoscopic and robotic prostatectomy compared with the open
approach.[54,69,70] It is unclear how this will translate into
disease-free and overall survival, since the laparoscopic and robotic
experience is still immature. Nonetheless, it is cause for concern.
Reference 70 refers to Guillonneau's presentation, the concluding
sentence in the abstract reads, "However, eradicating positive margins
at the distal prostatic apex remains a challenge."